DEVELOPMENT OF A FROZEN VASCULAR ENDOTHELIAL CELL PANEL

冷冻血管内皮细胞组的开发

• 批准号: 3489042
• 负责人: Lauren Brasile
• 金额: $ 5万
• 依托单位: VEC TEC, INC.
• 依托单位国家: 美国
• 财政年份: 1990
• 资助国家: 美国
• 起止时间: 1990-08-20 至 1991-02-19
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3489042
• 关键词: biomedical equipment development; cryopreservation; diagnosis design /evaluation; histocompatibility; histocompatibility typing; human tissue; vascular endothelium

VEC TEC, Inc. will develop a diagnostic test system consisting of a frozen panel of human vascular endothelial cells. The frozen panel will be used clinically to identify detrimental sensitization in patients awaiting a solid organ allograft. During Phase I, the cryopreservation techniques necessary for optimized viability of the endothelial cells will be developed. Issues pertaining to proper packaging of the test cells, as well as identifying appropriate lots of accompanying reagents will also be addressed during Phase I. A retrospective field trial, in collaboration with Brigham and Women's Hospital, will be initiated during Phase I to assess the potential clinical relevance of implementing this diagnostic test system. The proposed test system represents a novel approach to assessing histocompatibility and will serve as a supplemental assay the lymphocyte as the cell target in histocompatibility assays. However, rejection can be mediated by antibodies directed against antigens specific for vascular endothelial cells. The development of a frozen vascular endothelial cell panel may identify those patients at risk for early allograft rejection.

VEC TEC，Inc.将开发一种诊断测试系统，由冷冻的 人类血管内皮细胞的面板。将使用冻结的面板 在临床上识别等待治疗的患者的有害致敏作用 同种异体实体器官移植。在第一阶段，冷冻保存技术 内皮细胞的最佳活性所必需的是 发展起来的。与测试单元的正确包装有关的问题，如 以及确定适当的大量伴生试剂也将 在第一阶段期间解决，与合作进行回溯性现场试验 与布里格姆和妇女医院合作，将在第一阶段至 评估实施此诊断的潜在临床意义 测试系统。拟议的测试系统代表了一种新的方法 评估组织相容性，并将作为补充检测 以淋巴细胞为细胞靶点进行组织相容性分析。然而， 排斥反应可由针对特异性抗原的抗体介导。 对于血管内皮细胞。冷冻血管的发育 内皮细胞小组可能会识别那些有早期风险的患者 同种异体排斥反应。